Management of the interactions’ risks when using phytomedicines in children

Оlena Temirova; Yana Tarverdieva; Mykola Khaitovych; Volodymyr Sova; Kateryna Kyrylchuk

doi:10.32345/USMYJ.3(141).2023.160-166

Оlena Temirova Department of Clinical Pharmacology and Clinical Pharmacy of Bogomolets National Medical University, Kyiv, Ukraine
Yana Tarverdieva Department of Clinical Pharmacology and Clinical Pharmacy of Bogomolets National Medical University, Kyiv, Ukraine
Mykola Khaitovych Department of Clinical Pharmacology and Clinical Pharmacy of Bogomolets National Medical University, Kyiv, Ukraine
Volodymyr Sova National Children's Specialized Hospital «OKHMATDYT», Kyiv, Ukraine
Kateryna Kyrylchuk National Children's Specialized Hospital «OKHMATDYT», Kyiv, Ukraine

DOI: https://doi.org/10.32345/USMYJ.3(141).2023.160-166

Keywords: Child, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Herb-Drug Interactions, herbal medicine, Parents

Abstract

phytomedicines play an essential role in the treatment of children's diseases. Means of plant origin have a better safety profile, and due to the content of biologically active substances, they affect various links of pathological processes. However, data on the safety and efficacy of phytomedicines in children are limited and mostly derived from studies in adults. In addition, there are risks of pharmacokinetic and pharmacodynamic drug interactions. This study aims to study the risks of interaction when using phytomedicines and drugs in children. 100 parents participated in the study, most of whom had 1 or 2 children. An analysis of the pharmacotherapy courses of 50 children was also done. It has been established that parents when choosing medicines for children, consider their origin. Thus, more than 70 % of respondents consider phytomedicines to be safer for children and choose them for the treatment of acute respiratory viral infections (73 %), diseases of the throat (64 %), oral cavity (59 %), disorders of the gastrointestinal tract (28 %) and others. The phytomedicines of choice were: Chlorophyllip, Sinupret, Wormil Phyto, Proteflazid, Darsil, Cholelesan, etc., which 80 % of respondents used in combination with other medicinal products and without a doctor's prescription (75 % of respondents). It was revealed that 10 % of respondents noted the appearance of undesirable reactions after using phytomedicines, in combination with other medicinal products in children, the manifestations of which were: allergic reactions, digestive disorders, headache/dizziness. Based on the results of the analysis of the pharmacotherapy courses, it was established that the children received an average of 5.8 ± 1.7 medicines. In particular, 28 % received 2 or more phytomedicines. In more than 40 % of children, the risks of pharmacokinetic interaction of phytomedicines with other medicinal products were revealed. Thus, 10% received herbal remedies based on St. John's wort, which is a CYP3A4 inducer and reduces the effectiveness of albendazole, omeprazole, pantoprazole, and levocetirizine. While more than 30 % of children received products based on turmeric, silymarin, or grapefruit extract, which are strong CYP3A4 inhibitors. Risks of pharmacokinetic interaction at the stage of absorption (6 % of children) were associated with the use of flax and plantain seeds. In 10 % of children, the risk of pharmacodynamic interaction due to the use of thick eucalyptus leaf extract and an antiseptic agent was revealed. Therefore, when using phytomedicines in children, it is necessary to consider the risks of drug interactions. Phytomedicines can affect the pharmacokinetics of other drugs and change the realization of the clinical effect. When choosing and using phytomedicines the interaction of the doctor-pharmacist-parent is essential.

References

Amaeze, O., Marques, E. S., Wei, W., Lazzaro, S., Johnson, N., Varma, M. V. S., & Slitt, A. (2021). Evaluation of Nigerian Medicinal Plants Extract on Human P-glycoprotein and Cytochrome P450 Enzyme Induction: Implications for Herb-drug Interaction. Current Drug Metabolism, 22(14), 1103–1113. https://doi.org/10.2174/1389200223666211216142904

Antipkin, Y. G., Volosovets, О. P., Maidannik, V. G., Berezenko, V. S., Moiseenko, R. О., Vygovska, O. V., Krivopustov, S. P., Zabolotko, V. N., Aryaev, M. L., Abaturov, O. E., Kryuchko, T. O., Beketova, G. V., Kramarev, S. O., Petrenko, V. I., Levitsky, A. F., Marushko, Y. V., Shadrin, O. G., Mukvich, O. M., Mikichak, I. V., ... Mozyrskaya, O. V. (2018). Status of child population health — the future of the country (part 1). CHILD`S HEALTH, 13(1), 1–11. https://doi.org/10.22141/2224-0551.13.1.2018.127059

Antomonov M.Yu. Mathematical processing and analysis of biomedical data. 2nd edition K. : Mediinform, 2017. – 579 p.

Barkat, M. A., Goyal, A., Barkat, H. A., Salauddin, M., Pottoo, F. H., & Anwer, E. T. (2020). Herbal Medicine: Clinical Perspective & Regulatory Status. Combinatorial Chemistry & High Throughput Screening, 23. https://doi.org/10.2174/1386207323999201110192942

Bonate, P. L., Reith, K., & Weir, S. (1998). Drug Interactions at the Renal Level. Clinical Pharmacokinetics, 34(5), 375–404. https://doi.org/10.2165/00003088-199834050-00004

Chrubasik‐Hausmann, S., Vlachojannis, J., & McLachlan, A. J. (2018). Understanding drug interactions with St John's wort ( Hypericum perforatum L.): impact of hyperforin content. Journal of Pharmacy and Pharmacology, 71(1), 129–138. https://doi.org/10.1111/jphp.12858

Nicolussi, S., Drewe, J., Butterweck, V., & Meyer zu Schwabedissen, H. E. (2020). Clinical relevance of St. John's wort drug interactions revisited. British Journal of Pharmacology, 177(6), 1212–1226. https://doi.org/10.1111/bph.14936

Pharmacotherapy in pediatrics: a study guide / According to the general recommendation of Bilovola O.M. – Lviv: Publishing House of PP "Novy Svit – 2000", 2022. – 324 p.

Polat, S., & Gürol, A. (2021). Safety of Herbal Medicines in Children. У Alternative Medicine - Update. IntechOpen. https://doi.org/10.5772/intechopen.94545

Rithaporn T, Mongkolwongrojn M, Akarasereenont P, et al. (2007) Effect of grapefruit juice on pharmacokinetics of doxycycline in healthy volunteers. J Clin Pharm Ther. 32(3), 273-277. doi:10.1111/j.1365-2710.2007.00809.x.

Suroowan, S., & Mahomoodally, M. F. (2019). Herbal Medicine of the 21st Century: A Focus on the Chemistry, Pharmacokinetics and Toxicity of Five Widely Advocated Phytotherapies. Current Topics in Medicinal Chemistry, 19(29), 2718–2738. https://doi.org/10.2174/1568026619666191112121330

Volosovets, O. P., Bolbot, Y. K., Kryvopustov, S. P., Mozyrska, O. V., Kryvopustova, M. V., Prokhorova, M. P., & Kupkina, A. V. (2020). Bronchial asthma in children of Ukraine: medical and environmental parallels of morbidity and prevalence. Medicni perspektivi (Medical perspectives), 25(3), 184–191. https://doi.org/10.26641/2307-0404.2020.3.214861

Yang, L., & Tsai, T.-H. (2022). Neuroprotective effect and herbal-drug pharmacokinetic interaction of Gastrodia elata extract on valproic acid. Biomedicine & Pharmacotherapy, 156, 113938. https://doi.org/10.1016/j.biopha.2022.113938

Zelinska, N. B., Rudenko, N. G., Globa, E. V., Rudenko, O. V., Grishchenko, К., & Kavetska, Y. S. (2021). Diseases of the endocrine system in children in Ukraine and the provision of specialized care to pediatric patients in 2020. Ukrainian Journal of Pediatric Endocrinology, (2), 4–14. https://doi.org/10.30978/ujpe2021-2-4

Zhou, X., Fu, L., Wang, P., Yang, L., Zhu, X., & Li, C. G. (2021). Drug-herb interactions between Scutellaria baicalensis and pharmaceutical drugs: Insights from experimental studies, mechanistic actions to clinical applications. Biomedicine & Pharmacotherapy, 138, 111445. https://doi.org/10.1016/j.biopha.2021.111445

Management of the interactions’ risks when using phytomedicines in children

Abstract

References

Most read articles by the same author(s)